Q2
IDXX — Q2 2026 Financial Report Analysis
IDEXX grew Q2 2026 revenue 9.7% to $1.22 billion and diluted EPS 17.6% to $4.27 as recurring diagnostics grew 10.3% organically while instrument sales fell 19.5% against a launch-heavy prior year; 2026 EPS guidance was raised to $14.69–$14.94.